Brief: Journey Medical Corporation Expects Topline Results FromPhase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 For The Treatment Of Papulopustular Rosacea To Be Announced Week Of July 10
03/07/2023 13:12
July 3 (Reuters) - Journey Medical Corp DERM.O :
* JOURNEY MEDICAL CORPORATION EXPECTS TOPLINE RESULTS FROM
THE
PHASE 3 CLINICAL TRIALS (MVOR-1 AND MVOR-2) EVALUATING DFD-29
(MINOCYCLINE HYDROCHLORIDE MODIFIED RELEASE CAPSULES, 40 MG) FOR
THE TREATMENT OF PAPULOPUSTULAR ROSACEA TO BE ANNOUNCED WEEK OF
JULY 10, 2023
Source text for Eikon: ID:nGNX5wf4D0
Further company coverage: DERM.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Journey Medical
See all newsJourney Medical Corp expected to post a loss of 1 cent a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports
U.S. STOCKS ON THE MOVE-Five Below, Salesforce, IBM, Akamai Technologies